WO2023208986 - IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS
National phase entry:
Publication Number
WO/2023/208986
Publication Date
02.11.2023
International Application No.
PCT/EP2023/060891
International Filing Date
26.04.2023
Title **
[English]
IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS
[French]
DÉRIVÉS D'IMIDAZOLE EN TANT QU'INHIBITEURS D'ALK5
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
PIZZIRANI, Daniela
RONCHI, Paolo
BIAGETTI, Matteo
GUARIENTO, Sara
PALA, Daniele
Priority Data
22170302.8
27.04.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3041 | |
| EPO | Filing, Examination, Granting | 18280 | |
| Japan | Filing, Examination, Granting | 2688 | |
| South Korea | Filing, Examination, Granting | 3072 | |
| USA | Filing, Examination, Granting | 20990 |
Total:
48,071
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to compounds inhibiting the transforming growth factor β (TGF β) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many diseases, disorders, or conditions associated with ALK5 signaling pathway.[French]
La présente invention concerne des composés inhibant le récepteur du facteur de croissance transformant β (TGF β) de type I (ALK5) (ci-après inhibiteurs d'ALK 5), des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. Les composés de l'invention peuvent être utiles dans le traitement de nombreuses maladies, troubles ou états associés à la voie de signalisation ALK5.